Enliven seeks its reverse merger payday
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
AbbVie gets a cMet niche
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
Innovent takes the dual payload glory
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
